CME Activities

Please click the below image to begin our new Situation Room activity.

This Situation Room Activity is only compatible with Google Chrome and FireFox at this time. 

CLICK ON STATES TO SEE ACTIVITIES

Nov
8
Fri
A VR VIEW – Severe Uncontrolled Asthma: Phenotypes, Endotypes, and Treatment Response Decision
Nov 8 @ 8:00 pm – 9:15 pm

A VR VIEW – Severe Uncontrolled Asthma: Phenotypes, Endotypes, and Treatment Response Decision

A NON-CME FORUM

FRIDAY, NOVEMBER 8, 2019

8:00 pm – 8:15 pm Registration/Reception
8:15 pm – 9:15 pm Symposium

HILTON AMERICAS-HOUSTON
Room Name: Ballroom of the Americas Salons DE
1600 Lamar St.
Houston, Texas 77010

Mar
11
Wed
The Virtual Reality Room Targeting Type 2 Inflammation in Atopic Diseases: The Role of Interleukin Inhibitors
Mar 11 2020 @ 12:00 am – Mar 11 2021 @ 11:45 pm

The Virtual Reality Room
Targeting Type 2 Inflammation in Atopic Diseases: The Role of Interleukin Inhibitors

View Activity

FACULTY

William W. Busse, MD
Professor of Medicine
Division of Allergy, Pulmonary and Critical Care Medicine
University of Wisconsin School of Medicine and Public Health
Madison, WI

PROGRAM OVERVIEW

This online activity is focused on the team involved in the management of patients with type 2 inflammation in atopic diseases.

TARGET AUDIENCE

This activity is intended for U.S.-based pulmonologists, allergists, immunologists, otolaryngologists, pediatric/adolescent dermatologists, and other primary health care professionals (physicians, physician assistants, nurse practitioners) involved in the management of patients with atopic diseases including asthma, CRSwNP, and AD.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Describe the Th2 inflammatory pathways and cascades underlying the pathophysiology of atopic diseases including asthma, CRSwNP, and AD
  • Review the clinical profiles and mechanisms of action of interleukin inhibitors used for the treatment of atopic diseases including asthma, CRSwNP, and AD
  • Develop treatment plans for patients with atopic diseases including asthma, CRSwNP, and AD based on patient-specific factors relevant to clinical decision making

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this web-based activity for a maximum of 1.5 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

This program would be beneficial for nurses involved in the treatment and management of patients with DR.
CNE Credits: 1.5 ANCC Contact Hours.

ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.5 contact hours of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

FACULTY
William W. Busse, MD received consulting fees from Sanofi, Regeneron, AstraZeneca, GlaxoSmithKline, Genentech, Novartis. He serves on the Speakers Bureau for Regeneron, received royalty from Elsevier, and served on the Data Safety Monitoring Board for Boston Scientific.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Diana Tommasi, Director of Medical and Scientific Services, has nothing to disclose.
Ana Maria Albino, Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE
credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: March 11, 2020

EXPIRATION DATE: March 11, 2021

View Activity

 

Nov
11
Wed
Asthma BREATHE Grand Rounds Enduring Simulcast
Nov 11 2020 @ 12:00 am – Nov 11 2021 @ 11:59 pm

Asthma BREATHE Grand Rounds Enduring Simulcast

Immunological Targeting Approach for the Management of Moderate-to-Severe Asthma

View Activity

PROGRAM CHAIR

Nicola A. Hanania, MD, MS, FRCP(C), FCCP, FACP, FERS, ATSF (PROGRAM CHAIR)
Associate Professor of Medicine,
Director, Airway Clinical Research Center
Pulmonary, Critical Care and Sleep Medicine
Houston, TX

PROGRAM OVERVIEW

This program will review current and emerging therapies for the management of moderate-to-severe uncontrolled asthma.

TARGET AUDIENCE

This CME initiative is designed to meet the educational needs of pulmonologists, allergists, immunologists, and otolaryngologists involved in the healthcare of patients with moderate-to-severe uncontrolled asthma.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Review the molecular basis for the pathophysiology of moderate-to-severe asthma and the corresponding targeted biologic therapies
  • Describe the current medical committee guidelines and their application in clinical practice for the management of patients with moderate-to-severe asthma
  • Discuss the clinical trials data of biologic therapies as add-on treatments in the maintenance setting for patients with moderate-to-severe asthma

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with moderate-to-severe asthma.
Credits: 1.0 ANCC Contact Hour.

CNE Accreditation Statement: Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Faculty Member Disclosures
Nicola A. Hanania, MD, MS, FRCP(C), FCCP, FACP, FERS, ATSF

 

 

 

Served on the Speakers Bureau for AstraZeneca and worked as a consultant for GlaxoSmithKline, Boehringer Ingleheim, Genentech, Novartis, Sanofi, Regeneron and AstraZeneca, Teva and Amgen.  He has also done contracted research for GlaxoSmithKline, Boehringer Ingleheim, Sanofi, Genentech, Novartis and Gossamer

 

CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Chris Drury, MA, MS, MBA, Medical Director for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lauren Bartunek, Program Manager for Med Learning Group, has nothing to disclose.
Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete the online post-test and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based.

This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

 

View Activity

 

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only.  Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Nov
24
Tue
Application of VA Clinical Practice Guidelines in the Management of Asthma Enduring Activity
Nov 24 2020 @ 12:00 am – Nov 24 2021 @ 11:45 pm

Application of VA Clinical Practice Guidelines in the Management of Asthma Enduring Activity

View Activity

Jan
6
Wed
Nasal Polyps Grand Rounds Enduring
Jan 6 2021 @ 12:29 am – Jan 6 2022 @ 1:29 am

Addressing the Type 2 Inflammation Signature Through the Management of CRSwNP

FACULTY

Stella Lee, MD
Assistant Professor
Department of Otolaryngology
Director, Division of Sino-nasal Disorders and Allergy
University of Pennsylvania Medical Center
Pittsburgh, Pennsylvania

RELEASE DATE: January 6, 2021

EXPIRATION DATE: January 6, 2022

View Activity

May
11
Tue
Enduring Activity: BREATHE Asthma AMCP Symposium – Dr. Mario Castro and Dr. Geoffrey Wall | Targeted Approaches to the Management of Moderate-to-Severe Asthma: Implications for Managed Care – An Innovative View
May 11 2021 @ 9:12 am – May 11 2022 @ 10:12 am

Targeted Approaches to the Management of Moderate-to-Severe Asthma: Implications for Managed Care – An Innovative View

View Activity

FACULTY

Mario Castro, MD, MPH
Chief, Pulmonary, Critical Care and Sleep Medicine
Vice Chair for Clinical and Translational Research
Director, Frontiers: University of Kansas Clinical & Translational Science Institute
Director, Rainbow Clinical Trials Science Unit
University of Kansas School of Medicine
Kansas City, KS

Geoffrey C. Wall, PharmD, FCCP, BCPS
John R. Ellis Distinguished Chair of Pharmacy Practice
Professor of Clinical Sciences
Director, Drake Drug Information Center
Drake University College of Pharmacy and Health Sciences
Internal Medicine Clinical Pharmacist
Iowa Methodist Medical Center
Des Moines, IA

PROGRAM OVERVIEW

This enduring activity will cover the treatment and management of patients with moderate-to-severe asthma.


TARGET AUDIENCE

This CME initiative is designed to meet the educational needs of US-based managed care professionals who manage or are involved with the care of patients with moderate-to-severe asthma.


LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Discuss the patient and healthcare system burdens associated with asthma
  • Explain how the underlying molecular pathophysiology of moderate-to-severe asthma informs targeted biologic therapies
  • Apply current medical committee guidelines and recommendations for the management of patients with moderate-to-severe asthma in clinical practice
  • Utilize findings from clinical trials of biologic therapies as add-on treatments in the maintenance setting for patients with moderate-to-severe asthma

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with moderate-to-severe asthma.
Credits: 1.0 ANCC Contact Hour.

Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacists and Pharmacy Technicians
Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hour.
NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Mario Castro, MD, MPH serves on the speaker bureau for AstraZeneca, Genentech, GlaxoSmithKline, Regeneron, Sanofi, and Teva. He receives fees as a consultant for Genentech, Teva, Sanofi-Aventis and Novartis. He contracted research from AstraZeneca, GlaxoSmithKline, Pulmatrix, Sanofi-Aventis and Shinogi. He receives grant funding from AstraZeneca, GlaxoSmithKline, Pulmatrix, and Sanofi-Aventis.

Geoffrey C. Wall, PharmD, FCCP, BCPS serves on the speaker bureau for Janssen Pharmaceuticals and Tetraphase Pharmaceuticals.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Felecia Beachum, Program Manager for Med Learning Group, has nothing to disclose.
Marcello Morgan, MD, MPH, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certification as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making skills before applying any information, whether provided here or by others, for any professional use.

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

RELEASE DATE: May 11, 2021

EXPIRATION DATE: May 11, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/


ENDURING LEARNER NOTIFICATION

Med Learning Group
Targeted Approaches to the Management of Moderate-to-Severe Asthma: Implications for Managed Care – An Innovative View – ENDURING
May 11, 2021 – May 11, 2022
Online

Acknowledgement of Financial Commercial Support
Sanofi Genzyme and Regeneron Pharmaceuticals

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. You must attend the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacists and Pharmacy Technicians
Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hours.
UAN(s): JA4008163-9999-21-073-H04-P / JA4008163-9999-21-073-H04-T
NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.

Objectives – After Attending This Program You Should Be Able To

  1. Discuss the patient and healthcare system burdens associated with asthma.
  2. Explain how the underlying molecular pathophysiology of moderate-to-severe asthma informs targeted biologic therapies.
  3. Apply current medical committee guidelines and recommendations for the management of patients with moderate-to-severe asthma in clinical practice.

Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5).

All individuals in a position to control the content of CE are listed below:

Name Relationship: Commercial Interest
Felecia Beachum NA
Mario Castro Speaker Bureau: AstraZeneca, Genentech, GlaxoSmithKline, Regeneron, Sanofi. Consultant: Genentech, Teva, Sanofi-Aventis and Novartis. Contracted Research: AstraZeneca, GlaxoSmithKline, Pulmatrix, Sanofi-Aventis, Shinogi.
Matthew Frese NA
Christina Gallo NA
Brianna Hanson NA
Scott McGee-Plys NA
Marcello Morgan NA
Geoffrey C. Wall Speaker Bureau: Janssen Pharmaceuticals, Tetraphase Pharmaceuticals
Lauren Welch NA

How to Get Your Certificate

  1. Go to http://mlg.cmecertificateonline.com
  2. Click on “Targeted Approaches to the Management of Moderate-to-Severe Asthma: Implications for Managed Care – An Innovative View – ENDURING” link.
  3. Complete the post-test, click the provided link to go to the online evaluation site.
  4. Evaluate the meeting, click the provided link to open your credit certificate.
  5. Print/save all pages of your certificate for your records.

Questions?
Email Certificate@AmedcoEmail.com

View Activity

 

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. These CME activities are planned and produced in accordance with the ACCME Essentials.